Search the Newsreel

Regenxbio's Gene Therapy Shows 5-Year Vision Gains in AMD

Regenxbio reported five-year durability for its gene therapy, surabgene lomparvovec (sura-vec), showing stable to improved vision in patients with wet AMD after a single subretinal dose. These long-term results come ahead of pivotal Phase III data in Q4 2026, which will compare sura-vec against …

REGENXBIO (NASDAQ: RGNX) prices stock and warrant sale, netting $107.8M

REGENXBIO Inc. has priced an underwritten public offering of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant, expecting to net approximately $107.8 million after expenses, including the full exercise of the underwriters' 30-day option for …

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

REGENXBIO Inc. announced positive long-term data for its investigational gene therapy, surabgene lomparvovec (sura-vec), for wet Age-related Macular Degeneration (AMD) and diabetic retinopathy (DR). The data, presented at the ASRS Annual Meeting, showed durable efficacy and safety through five years for wet AMD patients …

REGENXBIO Stock Slides After $100M Equity Offering Shock

REGENXBIO Inc. (RGNX) stock dropped by 11.92% after announcing a $100 million public offering of common stock and pre-funded warrants at $9.00 per share to fund operations and pipeline development. This equity raise, coupled with a shareholder litigation firm investigating alleged misleading statements about …

REGENXBIO (NASDAQ: RGNX) launches $100M equity and pre-funded warrant raise

REGENXBIO Inc. (NASDAQ: RGNX) is conducting a primary offering of 10,003,889 shares of common stock and 1,111,111 pre-funded warrants for a total public offering price of $100 million. The public offering price is $9.00 per share and $8.9999 per warrant, with underwriters having a …

Regenxbio (RGNX) Launches $100 Million Public Offering

Regenxbio Inc. (RGNX) announced a public offering of common stock and pre-funded warrants aimed at raising approximately $100 million to support its gene therapy research and development. The company, which has a market cap of $579.01 million, has a GF Score of 60, indicating …

RGNX Stock Slides As $100M Offering And Legal Heat Hit

REGENXBIO Inc. (RGNX) stock is down over 9% following news of a planned $100 million public offering of common stock and a pending investigation into its officers and directors over alleged misleading statements related to a gene therapy trial. The offering aims to fund …

Regenxbio Shares Fall on $100M Stock, Pre-Funded Warrant Offering

Regenxbio (RGNX) announced a public offering of $100 million in common stock and pre-funded warrants. This financial move led to a significant 10% decline in the company's shares during after-hours trading. The offering includes standard stock and warrants, which can be exercised at a …

RGNX Stock Dips As Equity Offering And Litigation Raise Risk

REGENXBIO Inc. (RGNX) stock experienced a significant dip due to a bearish sentiment following a planned $100M public offering of common stock and ongoing shareholder litigation. The equity offering aims to fund its late-stage gene therapy pipeline but introduces dilution, while the lawsuit concerns …

REGENXBIO Raises $100M for Gene Therapy Pipeline

REGENXBIO Inc. (Nasdaq: RGNX) announced a proposed underwritten public offering to raise $100 million for its gene therapy pipeline. This funding comes as the company advances multiple late-stage programs, including RGX-202 for Duchenne muscular dystrophy and RGX-121 for Hunter syndrome, towards potential regulatory decisions …

Regenxbio prices $100m public offering at $9 per share

REGENXBIO Inc. has priced an underwritten public offering of common stock and pre-funded warrants at $9 per share, aiming to raise approximately $100.0 million. This capital raise comes after a nearly 20% stock decline and a reported negative free cash flow of $236 million …

RGNX Stock Slumps 15% After-Hours — What’s Driving The Selloff?

REGENXBIO Inc. (RGNX) shares dropped 15% after-hours following the announcement of a $100 million public stock offering, sparking dilution concerns among investors. The company, which specializes in gene therapies for rare diseases, has not specified how the new funds will be utilized but typically …

REGENXBIO (NASDAQ: RGNX) targets $100M stock sale to fund gene therapy

REGENXBIO Inc. (NASDAQ: RGNX) plans a primary offering of $100 million in common stock to fund general corporate purposes, including clinical trials and pipeline development. The company anticipates receiving a $100 million milestone payment from AbbVie in July 2026 and expects its total cash …

Regenxbio plans $100 million common stock offering

REGENXBIO Inc. (NASDAQ:RGNX) announced a $100 million public offering of common stock, which will be underwritten by Morgan Stanley, J.P. Morgan, Leerink Partners, and Mizuho. The company, focused on gene therapy for rare and retinal diseases, is rapidly burning through cash, with a negative …

REGENXBIO files prospectus for up to $100M common stock offering

REGENXBIO has filed a prospectus with the SEC for a common stock offering that could raise up to $100 million. The filing is a standard procedure that allows the company flexibility in future fundraising efforts. This move indicates potential plans to finance ongoing operations, …

REGENXBIO Announces Proposed Public Offering of Common Stock

REGENXBIO Inc. announced its intention to offer and sell $100 million of its common stock in an underwritten public offering, contingent on market conditions. The company also plans to grant underwriters a 30-day option to purchase up to an additional 15% of the shares …

RGNX Forecast — Price Target — Prediction for 2027

H.C. Wainwright Keeps Their Buy Rating on RegenXBio (RGNX)

Regenxbio (RGNX) Q1 2026 Earnings Transcript

Regenxbio Inc earnings missed by $0.38, revenue fell short of estimates

Regenxbio stock gains 4% on Duchenne trial win despite earnings miss

Duchenne gene therapy clears Phase III goal as REGENXBIO posts $90M loss

Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates

Duchenne gene therapy trial results are due in REGENXBIO webcast

RBC Capital Reaffirms Their Buy Rating on RegenXBio (RGNX)

REGENXBIO Q4 Earnings Call Highlights

REGENXBIO Inc. (NASDAQ:RGNX) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough

Is REGENXBIO (NASDAQ:RGNX) Weighed On By Its Debt Load?

REGENXBIO Earnings Results: $RGNX Reports Quarterly Earnings